Pharmaceutical Sector

Intellia Therapeutics (NTLA) Stock Price Could Touch $85 in Long Term: Morningstar Research

Intellia Therapeutics (NTLA) Stock Price Could Touch $85 in Long Term: Morningstar Research

Morningstar’s recent analysis suggests a "Buy" on Intellia Therapeutics, assigning a fair value of $85 per share, while the current trading price is significantly lower at $15.85.

Sanofi SA (ADR: SNY) Stock Price Could Reach $63: Morningstar Research

Sanofi SA (ADR: SNY) Stock Price Could Reach $63: Morningstar Research

Morningstar has issued a BUY recommendation on Sanofi SA, with an upgraded fair value target of $63 from $61 due to consistent revenue growth and strong performance in immunology and vaccine divisi

Longboard Pharmaceuticals Stock Price Jumps as Lundbeck A/S Acquires Controlling Stake for $60 per Share

Longboard Pharmaceuticals Stock Price Jumps as Lundbeck A/S Acquires Controlling Stake for $60 per Share

H. Lundbeck A/S, a prominent Danish pharmaceutical company, has announced its largest-ever acquisition, agreeing to buy U.S.-based Longboard Pharmaceuticals for $2.6 billion.

IPCA Laboratories Share Price in Focus as Motilal Oswal Suggests BUY Call with 18% Upside Potential

IPCA Laboratories Share Price in Focus as Motilal Oswal Suggests BUY Call with 18% Upside Potential

Motilal Oswal's research report has upgraded IPCA Laboratories to a "BUY" recommendation with a target price of Rs 1,950, an upside of 18% from its current market price of Rs 1,659.

Glenmark Pharmaceuticals Share Price in Focus After Ryaltris and Ciclopirox Gel Recall in US Market

Glenmark Pharmaceuticals Share Price in Focus After Ryaltris and Ciclopirox Gel Recall in US Market

Glenmark Pharmaceuticals Shares will be in focus today as the company has announced recall for two products in the US Market.

Gilead Sciences Stock Trades Flat; Neutral Rating by Zacks Research with $89 Price Target

Gilead Sciences Stock Trades Flat; Neutral Rating by Zacks Research with $89 Price Target

Gilead Sciences Inc.

Pages